IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Glioblastoma multiforme: a review of therapeutic targets
Kanu, Okezie O.2; Mehta, Ankit1; Di, Chunhui1; Lin, Ningjing3; Bortoff, Kathy1; Bigner, Darell D.1; Yan, Hai1; Adamson, David Cory1
关键词Genetics Glioblastoma Malignant Brain Tumor Malignant Glioma Oncogenomics Signaling Pathways
刊名EXPERT OPINION ON THERAPEUTIC TARGETS
2009-06-01
DOI10.1517/14728220902942348
13期:6页:701-718
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]EPIDERMAL-GROWTH-FACTOR ; PRIMARY INTRACRANIAL TUMORS ; COMPARATIVE GENOMIC HYBRIDIZATION ; PRIMARY BRAIN-TUMORS ; NEURAL STEM-CELLS ; IMMUNOLOGICALLY PRIVILEGED SITE ; RECURSIVE PARTITIONING ANALYSIS ; CPG ISLAND METHYLATION ; NERVOUS-SYSTEM TUMORS ; PRIMARY DE-NOVO
英文摘要

Glioblastoma is the commonest primary brain tumor, as well as the deadliest. malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest challenges in the management of cancer patients worldwide, despite notable recent achievements in oncology. Even with aggressive surgical resections using state-of-the-art preoperative and intraoperative neuroimaging, along with recent advances in radiotherapy and chemotherapy, the prognosis for GBM patients remains dismal: survival after diagnosis is about 1 year. Established prognostic factors are limited, but include age, Karnofsky performance status, mini-mental status examination score, O6-methylguanine methyltransferase promoter methylation and extent of surgery. Standard treatment includes resection of > 95% of the tumor, followed by concurrent chemotherapy and radiotherapy. Nevertheless, GBM research is being conducted worldwide at a remarkable pace, in the laboratory and at the bedside, with some of the more recent promising studies focused on identification of aberrant genetic events and signaling pathways to develop molecular-based targeted therapies, tumor stem cell identification and characterization, modulation of tumor immunological responses and understanding of the rare long-term survivors. With this universally fatal disease, any small breakthrough will have a significant impact on survival and provide hope to the thousands of patients who receive this diagnosis annually. This review describes the epidemiology, clinical presentation, pathology and tumor immunology, with a focus on understanding the molecular biology that underlies the current targeted therapeutics being tested.

语种英语
WOS记录号WOS:000267178800007
资助机构Janet Parsons in the Department of Pathology at Duke University
引用统计
被引频次:99[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53122
专题北京大学临床肿瘤学院
北京大学临床肿瘤学院_淋巴肿瘤内科
作者单位1.Duke & Durham VAMC, Durham, NC 27710 USA
2.Univ Lagos, Teaching Hosp, Lagos, Nigeria
3.Peking Univ, Sch Oncol, Beijing Canc Hosp, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Kanu, Okezie O.,Mehta, Ankit,Di, Chunhui,et al. Glioblastoma multiforme: a review of therapeutic targets[J]. EXPERT OPINION ON THERAPEUTIC TARGETS,2009,13(6):701-718.
APA Kanu, Okezie O..,Mehta, Ankit.,Di, Chunhui.,Lin, Ningjing.,Bortoff, Kathy.,...&Adamson, David Cory.(2009).Glioblastoma multiforme: a review of therapeutic targets.EXPERT OPINION ON THERAPEUTIC TARGETS,13(6),701-718.
MLA Kanu, Okezie O.,et al."Glioblastoma multiforme: a review of therapeutic targets".EXPERT OPINION ON THERAPEUTIC TARGETS 13.6(2009):701-718.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Kanu, Okezie O.]的文章
[Mehta, Ankit]的文章
[Di, Chunhui]的文章
百度学术
百度学术中相似的文章
[Kanu, Okezie O.]的文章
[Mehta, Ankit]的文章
[Di, Chunhui]的文章
必应学术
必应学术中相似的文章
[Kanu, Okezie O.]的文章
[Mehta, Ankit]的文章
[Di, Chunhui]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。